Thursday, May 28, 2020 9:32:00 AM
Recent MBRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:32:14 PM
- Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress • PR Newswire (US) • 05/16/2024 12:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:38:16 PM
- Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) • PR Newswire (US) • 05/15/2024 12:38:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:16:53 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/13/2024 02:53:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:30:14 AM
- Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/13/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:30:13 PM
- Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin • PR Newswire (US) • 05/09/2024 12:30:00 PM
- Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 05/08/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:13:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:55:19 PM
- Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data • PR Newswire (US) • 05/07/2024 12:55:00 PM
- Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 • PR Newswire (US) • 05/02/2024 01:00:00 PM
- Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin • PR Newswire (US) • 05/01/2024 12:50:00 PM
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) • PR Newswire (US) • 04/18/2024 12:30:00 PM
- Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties • PR Newswire (US) • 04/10/2024 12:30:00 PM
- Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference • PR Newswire (US) • 03/28/2024 02:45:00 PM
- Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity • PR Newswire (US) • 03/27/2024 01:25:00 PM
- Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML • PR Newswire (US) • 03/27/2024 01:05:00 PM
- Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial • PR Newswire (US) • 03/25/2024 11:30:00 AM
- Moleculin Reports Full Year 2023 Financial Results • PR Newswire (US) • 03/22/2024 08:05:00 PM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM